Freescale Semiconductor Ltd (NYSE:FSL) up by 4.44%, Alkermes Plc (NASDAQ:ALKS)

Posted by Lynn Eisler May 13, 2013 0 Comment 1682 views


Freescale Semiconductor Ltd (NYSE:FSL): Friday’s trading session saw Freescale Semiconductor Ltd (NYSE:FSL) shares gain 4.44%. The opening price of $15.44, moved on to touch an intraday high of $16.23 before sliding down to $15.40 per share. More than 2.30 million shares changed hands in the trading session on Friday. This number was more than the average volume of 1.86 million which was calculated over a 30-day period.

Freescale Semiconductor Ltd (NYSE:FSL) has just launched the multi-core communications processor, QorIQ T4240. This processor has raised the bar by breaking a CoreMark record that it had previously set. This had also been for an embedded system-on-chip processor. The QorIQ T4240 processor uses advanced compiler technology. This has raised its CoreMark score from 179,763-187,873.

Freescale Semiconductor Ltd (NYSE:FSL) is a manufacturer of microcontrollers, semiconductors and microprocessors. It offers microcontroller solutions, like components for embedded control systems. These include microcontrollers, embedded microprocessors and embedded processors. Processors such as these are used in consumer, automotive, industrial and computer peripheral applications. Freescale also supplies products to connectivity wireless, automotive, networking, energy, consumer, motor control, and the industrial markets.

Alkermes Plc (NASDAQ:ALKS): Friday’s trading session saw Alkermes Plc (NASDAQ:ALKS) shares gaining 4.31 %. The opening price of $29.99, moved on to touch an intraday high of $31.35 before sliding down to $29.78 per share. More than 1.20 million shares changed hands in the trading session on Friday. This number was less than the average volume of 1.61 million which was calculated over a 30-day period.

Alkermes Plc (NASDAQ:ALKS) was previously known as Alkermes, Inc. It is an integrated bio-technology company and is involved in developing, manufacturing as well as commercialization of various medicines. These are used in the treatment of prevalent and chronic diseases. VIVITROL the drug for treating alcohol dependence is developed, manufactured and commercialized by the company. It also manufactures RISPERDAL CONSTA which is used in the treatment of bipolar I disorder and schizophrenia.  Its pipeline is inclusive of oral and extended-release products as well as injectables. These are used in the treatment of prevalent, chronic diseases like reward disorders, autoimmune disorders, central nervous system disorders addiction and diabetes. On 16 September 2011, Alkermes Plc (NASDAQ:ALKS) merged with Elan Corporation’s drug formulation and manufacturing business unit, Elan Drug Technologies.


About Lynn Eisler

Lynn Eisler is a national news reporter focusing on economic issues, data analysis and the financial health of state and local governments. Lynn has been honored with the H.L. Mencken Award for Investigative Reporting, the Champion of Justice Award for reporting on the drug war, and the John Hancock Award for business reporting. Lynn was also a Knight Medical School Fellow at the University of Michigan.

View all post by Lynn Eisler Visit author's website

Write Your Comment